Rising Incidence of Non-Cardia Gastric Cancer among Young Women in the United States, 2000–2018: A Time-Trend Analysis Using the USCS Database
by
, , ,
Janice Oh
1,
Yazan Abboud
2,
Miguel Burch
1,
Jun Gong
1,
Kevin Waters
1,
Jenan Ghaith
2,
Yi Jiang
2,
Kenneth Park
2,
Quin Liu
2,
Rabindra Watson
2,
Simon K. Lo
2 and
Srinivas Gaddam
2,* 1
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2
Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(8), 2283; https://doi.org/10.3390/cancers15082283
Submission received: 20 March 2023
/
Revised: 10 April 2023
/
Accepted: 12 April 2023
/
Published: 13 April 2023
(This article belongs to the Special Issue Clinical and Translational Research in Gastrointestinal Cancers)
Abstract
:Simple Summary
Although the global incidence of non-cardia gastric cancer (NCGC) is decreasing, there are limited data on sex-specific incidence in the U.S. The aim of our study was to investigate age and sex-specific time trends of NCGC incidence using a large national database from the Surveillance, Epidemiology, and End Results (SEER) Program, and thereafter to externally validate these findings within an independent population-based database, the National Program of Cancer Registries (NPCR). We evaluated the influence of race, histopathology, and disease stage at diagnosis on these trends. NCGC incidence has been relatively increasing at a greater rate in younger women compared to counterpart men over the last two decades, and this rise may be explained by a disproportionate increase in young non-Hispanic White women. Our findings support the increasing incidence of cancers at multiple sites in young women, and emphasize the need for dedicated research to determine the etiologies of these alarming trends.
Abstract
Introduction: Although the global incidence of non-cardia gastric cancer (NCGC) is decreasing, there are limited data on sex-specific incidence in the United States. This study aimed to investigate time trends of NCGC from the SEER database to externally validate findings in a SEER-independent national database, and to further assess trends among subpopulations. Methods: Age-adjusted incidence rates of NCGC were obtained from the SEER database from 2000 to 2018. We used joinpoint models to calculate average annual percentage change (AAPC) to determine sex-specific trends among older (≥55 years) and younger adults (15–54 years). Using the same methodology, findings were then externally validated using SEER-independent data from the National Program of Cancer Registries (NPCR). Stratified analyses by race, histopathology, and staging at diagnosis were also conducted in younger adults. Results: Overall, there were 169,828 diagnoses of NCGC from both independent databases during the period 2000–2018. In SEER, among those <55 years, incidence increased at a higher rate in women (AAPC = 3.22%, p < 0.01) than men (AAPC = 1.51%, p = 0.03), with non-parallel trends (p = 0.02), while a decreasing trend was seen in both men (AAPC = −2.16%, p < 0.01) and women (AAPC = −1.37%, p < 0.01) of the ≥55 years group. Validation analysis of the SEER-independent NPCR database from 2001 to 2018 showed similar findings. Further stratified analyses showed that incidence is disproportionately increasing in young non-Hispanic White women [AAPC = 2.28%, p < 0.01] while remaining stable in their counterpart men [AAPC = 0.58%, p = 0.24] with non-parallel trends (p = 0.04). This pattern was not observed in other race groups. Conclusion: NCGC incidence has been increasing at a greater rate in younger women compared to counterpart men. This disproportionate increase was mainly seen in young non-Hispanic White women. Future studies should investigate the etiologies of these trends.
1. Introduction
Over one million new cases of gastric cancer were reported worldwide in 2020 and it is the fourth leading cause of cancer mortality [1]. By 2022, the incidence of gastric cancer in the U.S. was estimated to be over 26,000 cases, higher than that of esophageal, small intestine, or biliary cancer [2]. The 5-year survival rate in the U.S. is estimated to be about 32.4% [3], which significantly decreases to 6% in advanced metastatic stages [4]. With disease progression, patients experience deteriorating symptoms that cause significant psychological distress [5]. Furthermore, with its high recurrence rate of up to 60% in the recent literature [6], healthcare for surveillance, maintenance, and treatment of gastric cancer is costly and resource-intensive [7].
Of the two anatomical subtypes of gastric cancer, non-cardia gastric cancer (NCGC) is associated with different pathophysiology and risk factors than cardia gastric cancer, which behaves like, and is frequently diagnosed as, esophageal adenocarcinoma [8]. Thus, to understand the burden of gastric cancer alone, it is important to study the epidemiology of primary NCGC. A study using the 45 North American Association of Central Cancer Tumor Registries demonstrated an increasing trend of NCGC incidence in younger individuals, with the trend being more pronounced in women than men [9]. However, age and sex-specific incidence trends of subpopulations, such as in younger non-Hispanic White women, are currently limited in the literature. With a recent rise in gastrointestinal cancers in younger individuals, it is crucial to quantify subgroup risks using large population databases to uncover age and sex-specific trends that may be masked, especially in young individuals.
The overall objective of this study was to assess the incidence trends of NCGC in a nationally representative sample. We aimed to investigate age and sex-specific time trends of NCGC incidence in the U.S. using a large database from the Surveillance, Epidemiology, and End Results (SEER) Program, and thereafter to externally validate these findings within an independent population-based database, the National Program of Cancer Registries (SEER-independent NPCR). Secondarily, we also evaluated the influence of risk factors including race, histopathology, and disease stage at diagnosis on these age and sex-specific trends using the SEER database.
2. Methods
To evaluate the time trends of NCGC incidence rates in the U.S., we obtained data from 1 January 2000 to 31 December 2018 from the SEER database. We used data from 1 January 2001 to 31 December 2018 from the NPCR database for external validation. Both databases are publicly available with de-identified patient information, and therefore this study was exempt from IRB review based on our institutional policy.
2.1. Databases and Exclusion Criteria
The SEER 21 Program has been funded by the National Cancer Institute (NCI) to collect cancer statistics from 19 geographic regions, encompassing approximately 34.6% of the U.S. population [10]. Alternatively, the NPCR is funded by the Centers for Disease Control and Prevention (CDC) to collect data from cancer registries in 46 states, the District of Columbia, Puerto Rico, the U.S. Pacific Island Jurisdictions, and the U.S. Virgin Islands [10]. We used SEER data in their entirety, including all state and regional registries. For the steps of external validation, we excluded state cancer registries from the NPCR database that also reported data in part or in full to SEER, resulting in the ‘SEER-independent NPCR database’. The states that were excluded were Alaska, California, Connecticut, Georgia, Hawaii, Idaho, Iowa, Kentucky, Louisiana, Massachusetts, New Jersey, New Mexico, New York, Utah, and Washington [8]. The ‘SEER-independent NPCR database’ consisted of cancer statistics from 35 states and Washington D.C., covering nearly 64.5% of the U.S. population (Supplementary Figure S1) [11]. Thus, this study evaluated the NCGC incidence trends from two nationally representative databases that collectively cover approximately 100% of the U.S. population. Data were obtained from the SEER and NCPR databases using SEER*Stat software, v8.4.0.1 (NCI, Bethesda, MD, USA).
NCGC was defined as cancer in all regions of the stomach, except for the cardia. We excluded data points with any cardia involvement, including cardia, overlapping, and unspecified subsites (ICD-10 codes 16.0, 16.8, 16.9). Only cancers of non-cardia gastric origin were included in the study, and cases of leukemia, lymphoma, mesothelioma, or Kaposi’s sarcoma cancers (ICD-O-3 codes 9050-9055, 9140, 9590-9989) were excluded from all analyses [12].
2.2. Statistical Analysis
The incidence rates were adjusted to reporting delay and age to the 2000 US population, and the age-standardized incidence rate (aIR) was defined as the number of individuals diagnosed with NCGC per 100,000 population per year. We conducted a time-trend analysis of the quantified rates using the Joinpoint Regression Program, version 4.9.1 (NCI, Bethesda, MD, USA). This software program performs the Monte Carlo permutation method to determine the simplest joinpoint model that best fits the time trend of the NCGC incidence rates from the SEER and SEER-independent NPCR datasets [13]. Following the fitting of the model, the program quantifies the rate trends in annual percentage changes (APC) with its average (AAPC), and tests the statistical difference from zero using a two-tailed test (p-value < 0.05) based on asymptotic normality and the calculated variances of the estimated joinpoint segments [14]. The trends were considered stable if AAPC p-values were non-significant. Increasing or decreasing trends had AAPC values that were positive or negative, respectively. Furthermore, pairwise comparison tests are conducted to compare the sex-specific trends for parallelism and identicalness, using the test of parallelism and test of coincidence, respectively, under the assumption of uncorrelated errors with constant variance [15]. The test of parallelism assessed if the incidence trends were parallel based on the AAPCs of the linear joinpoint segments. A statistically significant result indicated a difference between the estimated slopes of the two independent comparison groups, and p-values < 0.05 signified that the two time trends were neither parallel nor identical. Subsequently, we evaluated trends by risk factors with a cutoff age at 55 years to determine trends among older (≥55 years) and younger adults (15–54 years). The trends were considered significant using a 2-tailed t-test (p-value < 0.05). Thereafter, the same analysis was performed in the SEER-independent NPCR database for external validation.
Lastly, to distinctively investigate trends in younger adults, analyses of sex-specific trends were further stratified by race, histopathology, and staging at diagnosis. Self-reported race and ethnicity data were extracted from medical records and categorized into non-Hispanic White, non-Hispanic Black, Hispanic, Asian, and others [16]. Lauren’s criteria were applied to classify cases of NCGC into histology groups of intestinal, diffuse, and other (unspecified) subtypes [8]. ICD-O-3 codes for each subtype group were established on the basis of prior studies [9,12] and included the most common histopathology diagnoses. Staging at diagnosis was grouped into localized, regional, distant, and unknown/unstaged. Of note, the data for staging at diagnosis are from 2004 to 2018, as the staging collection and reporting process in SEER changed for all registries in 2004 [11]. Given that the race grouping options were limited in the SEER-independent NPCR database, we assessed these trends using the SEER database only.
3. Results
3.1. Discovery Phase: SEER Database 2000–2018
3.1.1. Overall Rates and Trends
According to the SEER database, a total of 79,068 patients were diagnosed with NCGC during the period 2000–2018. The overall aIR of NCGC in men (4.44, 95% CI 4.39–4.48) was higher than in women (2.91, 95% CI 2.88–2.94) (Table 1). As seen in Table 2A, the overall trends were significantly decreasing in both men [AAPC = −1.73% (−1.94–−1.51%); p < 0.01] and women [AAPC = −0.60% (−0.80–−0.40%); p < 0.01]. The sex-specific trends were both non-parallel and non-identical (both p < 0.01), suggesting that incidence rates in men and women were both decreasing but at different rates.
3.1.2. Sex-Specific Trends by Age Groups
Among those aged ≥55 years, trends were decreasing in both men [AAPC = −2.16% (−2.38–−1.95%); p < 0.01] and women [AAPC = −1.37% (−1.61–−1.12%); p < 0.01] (Figure 1A). The sex-specific trends were neither parallel nor identical (both p < 0.01).
Of those younger than 55 years (15–54), a total of 13,791 individuals (47.7% women) were diagnosed with NCGC during 2000–2018. The overall aIR of NCGC in men (1.21, 95%CI 1.18–1.24) was higher than in women (1.09, 95%CI 1.06–1.11). Overall trends of the aIRs significantly increased in both men [AAPC = 0.68% (0.06–1.30%); p = 0.03] and women [AAPC = 2.28% (1.82–2.74); p < 0.01]. However, as seen in Figure 1B, the NCGC incidence rate in women surpassed that in men after 2016. The two sex-specific trends were neither parallel (p = 0.02) nor identical (p < 0.01).
3.2. External Validation Phase: SEER-Independent NPCR Database 2001–2018
3.2.1. Overall Rates and Trends
After the exclusion of 78,757 individuals that were also reported to the SEER Program, a total of 90,760 patients were diagnosed with NCGC from 2001 to 2018 in the SEER-independent NPCR database. The overall incidence rate of NCGC in men (3.06, 95%CI 3.03–3.09) was also higher than in women (2.03, 95%CI 2.01–2.05). Notably, the mean trend was significantly decreasing in men [AAPC = −1.55% (−2.37–−0.73%); p < 0.01], while remaining stable in women [AAPC = −0.19% (−0.98–−0.61%); p = 0.65]. The sex-specific trends were both non-parallel and non-identical (both p < 0.01; Table 2B).
3.2.2. Sex-Specific Trends by Age Groups
As demonstrated in Figure 1C, among men and women of ages ≥55 years, mean sex-specific trends of this subgroup were decreasing in both men [AAPC = −2.06% (−3.01–−1.11%); p < 0.01] and women [AAPC = −0.82% (−1.22–−0.43%); p < 0.01]. The trends were non-parallel and non-identical (both p < 0.01).
Of those younger than 55 years (15–54), a total of 15,486 individuals (47.4% women) were diagnosed with NCGC during 2001–2018. The overall sex-specific incidence rate of NCGC in men (0.88, 95%CI 0.86–0.90) was higher than in women (0.79, 95%CI 0.77–0.81). The incidence increased in both men [AAPC = 1.51% (1.04–1.98%); p < 0.01] and women [AAPC = 3.22% (2.69–3.77%); p < 0.01]. As also seen in Figure 1D, the NCGC incidence rate in women surpassed that in men after 2016.The two sex-specific trends were neither parallel nor identical (both p < 0.01).
3.3. Evaluation of Risk Factors among Young Adults
3.3.1. Sex-Specific Trends by Race/Ethnicity
The overall incidence rates were higher in non-Hispanic Blacks (1.80, 95%CI 1.73–1.87), Hispanics (1.97, 95%CI 1.91–2.03), and Asians/Pacific Islanders (2.02, 95%CI 1.94–2.11) compared to non-Hispanic Whites (0.62, 95%CI 0.60–0.64), seen in both men and women (Table 1). The time trends were parallel among men and women in non-Hispanic Blacks, Hispanics, and Asians/Pacific Islanders (all p > 0.05). Notably, despite lower incidence rates in both sexes, the incidence trend in younger non-Hispanic White adults was increasing in women [AAPC = 2.28% (1.38–3.19%); p < 0.01] while stable in their counterpart men [AAPC = 0.58% (−0.42–1.59%); p = 0.24] (Figure 2). Further, the sex-specific trends in younger non-Hispanic Whites were neither parallel (p = 0.04) nor identical (p < 0.01).
3.3.2. Sex-Specific Trends by Histopathology
Based on Lauren’s classification, there were more cases of diffuse or unspecified subtypes of NCGC (5280 total diffuse; 7010 total unspecified) than the intestinal subtype (1364 total intestinal) from 2000 to 2018 in the younger population (Table 3). When stratified by subtypes, incidence rates were lower in women than men for intestinal (aIRR 0.53) and unspecified subtypes (aIRR 0.87), while higher among the diffuse subtype (aIRR 1.07). Both sex groups had an increasing incidence of intestinal and diffuse subtypes of NCGC, with parallel trends (both p > 0.05) (Figure 3 and Supplementary Figure S2). Notably, of the unspecified subtype, women had a statistically significant increase in the incidence trend [AAPC = 3.62% (2.99–4.26%) p < 0.01] while the trends in men were stable [AAPC = 0.43% (−0.40–1.21%); p = 0.26]. Both sex-specific trends were neither parallel nor identical (both p < 0.01).
3.3.3. Sex-Specific Trends by Staging at Diagnosis
When stratified by staging at diagnosis, women had higher overall incidence than men in localized stages during the time period 2004–2018. On the contrary, overall incidence rates in men were higher in regional and distant stages than in women. Notably, in those diagnosed with localized primary NCGC, the incidence trend was increasing in women [AAPC = 5.17% (4.04–6.31%); p < 0.01] at a greater rate than in men [AAPC = 2.04% (0.33–3.78%); p = 0.02]. The trends were neither parallel nor identical (both p = 0.03). As seen in Figure 4, the time trends in both sexes were parallel in regional, distant, and unknown subgroups (all p > 0.05).
4. Discussion
This study is among the largest and most updated population-based analyses evaluating the incidence time trends of primary NCGC in the U.S. from 2000 to 2018. We found that among 79,068 individuals diagnosed with NCGC from the SEER database, the overall rates have been decreasing in the U.S for both men and women. However, when stratified by sex and age, the incidence rates are increasing in younger women (15–54 years) at a greater rate than in young men, with women surpassing men in rates after 2016. Our external validation phase using the SEER-independent NPCR dataset of 90,760 individuals found similar results of the incidence trends.
Despite similar findings, there were small differences in the analysis results. Joinpoints are included in the regression models of SEER-independent NPCR data, specifically in both sexes of ‘all ages’ and in the subgroup of men ≥55 years of age. These slight differences between datasets may possibly be due to variation in sample sizes, as more significant trend changes can be detected with larger sample sizes [17]. We can also consider geographical differences in data collection for each database that may influence demographic and environmental factors that correlate to NCGC incidence. Nonetheless, the primary conclusion from each analysis of the two independent databases is the same: the overall NCGC incidence rate appears to be decreasing over the past two decades while increasing at a greater rate in young women compared to their counterpart men.
In the further evaluation of risk factors in NCGC, there were no statistically significant differences in incidence trends between younger men and women with intestinal or diffuse histopathology subtypes. In contrast, among those with an unspecified subtype, women had a markedly increasing incidence rate of NCGC from 2000 to 2018 compared to their counterpart men. Although this may suggest an underlying sex discrepancy in NCGC incidence by histopathology, it is difficult to make definitive conclusions due to limitations of incomplete data reporting and lack of heterogeneity in unspecified histology subtypes, as more than two-thirds consisted of undifferentiated adenocarcinoma. When stratified by staging at diagnosis, the incidence trend of localized primary NCGC was increasing in women at a greater rate than in men during 2004–2018. Meanwhile, time trends in both sexes were parallel in regional, distant, and unknown subgroups (all p > 0.05). The reasons for the discrepancy seen in localized stages are unknown, although the H. pylori infection mechanism and epigenetics that influence the pathophysiology of NCGC cellular spread may be possibilities.
We also found that among young adults, despite higher incidence rates in both sexes of Hispanics, non-Hispanic Blacks, and Asians, the trend of incidence over the past two decades is markedly increasing in non-Hispanic White women while remaining stable in non-Hispanic White men. Based on our APC comparisons, primary NCGC incidence in young non-Hispanic White women has been increasing at a rate nearly four times that of their counterpart men over the last two decades. The disproportionate increase is consistent with findings by Anderson et al.; however, our study quantifies the discrepancy between the focused cohorts using more recent data. It is also important to note that the increase in NCGC incidence was statistically significant in both young Hispanic men and women with parallel time trends, differing from the conclusions of studies that have demonstrated a higher increasing rate in one sex than another [18,19]. Despite the inconsistent findings in the recent literature, further evaluation of this trend among young Hispanics is warranted.
Many studies in the existing literature have investigated the incidence of gastric cancer and its associated risk factors in global settings. It is widely accepted that H. Pylori infections predispose individuals to NCGC [20], and H. pylori transmission dynamics may be playing a role in the increasing NCGC incidence in young women. Prior studies demonstrate that H. pylori is a strong risk factor for gastric cancer in younger non-Hispanic White women, in whom H. pylori infection prevalence had been previously low, making them new, vulnerable hosts [21]. A review by Thrift et al. also explores risk factors for developing gastric cancer from H. pylori infections, such as reduction in gastric acid secretion from oxyntic atrophy of the gastric fundus or body, and different carcinogenic potential based on various strains and virulence factors such as cytotoxin-associated-gene A (cagA) [22]. Thus, future studies can be guided to assess the incidence of cagA+ strain infections in young women compared to men or older women, and to determine any differences in oxyntic atrophy and gastric acidity levels among various population subgroups. More importantly, additional research entailing cost-effectiveness analysis in H. pylori screening strategies in young women is warranted.
In addition to H. pylori infections, the increasing NCGC incidence trend in young non-Hispanic White women can be attributed to changes in gut microbiota [23], differences in hormone exposure [24], and effects from tobacco and alcohol use [25]. Additionally, genetic factors seem to affect females to a greater degree than males [26,27], suggesting that exposure risks and epigenetic processes may be contributing to the increase in incidence. The current literature, from a genetic standpoint, suggests a higher risk for gastric cancer from microsatellite instability, which is more associated with women but of older age (>65 years) [28]. Furthermore, it can be hypothesized that the disproportionate increase in NCGC incidence trend in younger women is associated with genetically-predisposed autoimmunity. Notably, autoimmune gastritis (AIG) is three times more common in women than men [29]. A recent cohort study found that antibodies of AIG were associated with increased gastric cancer risk, being strongest in non-cardia locations [30]. There was also speculation of more antibiotics and proton-pump inhibitor (PPI) therapy use in women than men [31], which alter the gut microbiome potentially eliciting an inflammatory response. Altogether, the higher risk for autoimmunity and medication-induced inflammatory states in young women than men may play a role in the sex-specific differences in primary NCGC incidence seen in this study.
There are strengths and limitations to this study. A notable strength is that this study is the largest population-based study to date which evaluates NCGC incidence time trends in the U.S., covering nearly 100% of the U.S. population. The use of two independent cohorts with 2018 data offers more accurate estimates of the current incidence trend. Secondly, data extracted from the SEER database were adjusted for reporting delay, which is important in precisely determining updated trends [32]. Lastly, this study conducted external validation to demonstrate the reproducibility of its findings. One limitation is that there may be a small overlap between the SEER and SEER-independent NPCR databases, despite the exclusion of registries. However, we removed more than 79,000 data points with the state-wide exclusion method, and the small overlap is estimated to be approximately less than 1%. Another limitation of this study was the smaller sample sizes of the younger adults when using only the SEER database for the secondary analyses instead of both databases combined. Due to limited race grouping availabilities for the NPCR database, we opted to use only the SEER database to evaluate the incidence trends among more focused race subgroups. Moreover, it is unclear if race and ethnicity self-identification represents ancestry or whether it is culture-based, especially in individuals of mixed races. As initial race and ethnicity data are charted by the providers, there may be some inconsistency in assignment and coding as there is no standardized collection method used across all facilities.
5. Conclusions
Based on two independent population databases to cover nearly 100% of the U.S. population, NCGC incidence rates were relatively increasing in younger women compared to younger men over the last two decades. Furthermore, there is an increasing trend in young non-Hispanic White women compared to counterpart men. Our findings support the increasing incidence of cancers at multiple sites in young women [33], although the reasons for these alarming trends remain elusive. Thus, future studies should investigate linked or separate etiologies of these trends to decrease the overall burden of primary NCGC in the future with newly developed screening or preventive measures.
Supplementary Materials
The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/cancers15082283/s1, Figure S1: Flowchart—Study sample inclusion and distribution by database, sex, and age; Figure S2: Age–sex pyramid—Overall incidence rates of primary NCGC in young adults (<55 years old) by race groups from SEER database (2000–2018).
Author Contributions
Conceptualization, J.O. and S.G.; methodology, J.O., Y.A. and S.G.; software, J.O. and Y.A.; validation, J.O. and S.G.; formal analysis, J.O. and Y.A.; investigation, J.O., Y.A. and S.G.; resources, J.O. and S.G.; data curation, J.O.; writing—original draft preparation, J.O. and S.G.; writing—review and editing, J.O., Y.A., M.B., J.G. (Jun Gong), K.W., J.G. (Jenan Ghaith), Y.J., K.P., Q.L., R.W., S.K.L. and S.G.; visualization, J.O.; supervision, S.G.; project administration, J.O. and S.G.; funding acquisition, S.K.L. and S.G. All authors have read and agreed to the published version of the manuscript.
Funding
This study was partly supported with funding received from the AGA Research Scholar Award of the American Gastroenterology Association Research Foundation. (S.G.’s protected time by this grant enabled the completion of this project.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
All primary non-cardia gastric cancer incidence data used in this study are openly available from the CDC’s NPCR and NCI’s SEER program, which can be accessed through the SEER*Stat software (v8.4.0.1).
Acknowledgments
The study is partly funded by the Widjaja Family Fund for Pancreatic Cancer Research, Grow@Annenberg Foundation©, and Caroline Dann. We would like to acknowledge Shelly Lu and Stephen Pandol who have provided support and guidance through this project.
Conflicts of Interest
The authors declare no conflict of interest.
Abbreviations
| aIR | Age-adjusted incidence rates |
| aIRR | Age-adjusted incidence rate ratio |
| APC | Annual percentage change |
| AAPC | Average annual percentage change |
| AIG | Autoimmune gastritis |
| CDC | Centers of Disease Control and Prevention |
| NCI | National Cancer Institute |
| NCGC | Non-cardia gastric cancer |
| NPCR | National Program of Cancer Registries |
| PPI | Proton-pump inhibitor |
| SEER | Surveillance, Epidemiology, and End Results |
| USCS | United States Cancer Statistics |
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33. [Google Scholar] [CrossRef] [PubMed]
- Cancer of the Stomach-Cancer Stat Facts. Available online: https://seer.cancer.gov/statfacts/html/stomach.html (accessed on 31 December 2022).
- Stomach (Gastric) Cancer Survival Rates. Available online: https://www.cancer.org/cancer/stomach-cancer/detection-diagnosis-staging/survival-rates.html (accessed on 31 December 2022).
- Rupp, S.K.; Stengel, A. Influencing Factors and Effects of Treatment on Quality of Life in Patients With Gastric Cancer-A Systematic Review. Front. Psychiatry 2021, 12, 656929. [Google Scholar] [CrossRef] [PubMed]
- Spagnuolo, R.; Corea, A.; Blumetti, M.; Giovinazzo, A.; Serafino, M.; Pagliuso, C.; Pagnotta, R.; Curto, G.; Cosco, C.; Cosco, V.; et al. Effects of listening to music in digestive endoscopy: A prospective intervention study led by nursing. J. Adv. Nurs. 2020, 76, 2993–3002. [Google Scholar] [CrossRef] [PubMed]
- Abraham, P.; Wang, L.; Jiang, Z.; Gricar, J.; Tan, H.; Kelly, R.J. Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer. Future Oncol. 2021, 17, 291–299. [Google Scholar] [CrossRef] [PubMed]
- Hu, B.; El Hajj, N.; Sittler, S.; Lammert, N.; Barnes, R.; Meloni-Ehrig, A. Gastric cancer: Classification, histology and application of molecular pathology. J. Gastrointest. Oncol. 2012, 3, 251–261. [Google Scholar]
- Anderson, W.F.; Rabkin, C.S.; Turner, N.; Fraumeni, J.F., Jr.; Rosenberg, P.S.; Camargo, M.C. The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites. J. Natl. Cancer Inst. 2018, 110, 608–615. [Google Scholar] [CrossRef] [Green Version]
- National Program of Cancer Registries and Surveillance, 2020 Submission (2001–2018). Available online: https://www.cdc.gov/cancer/uscs/public-use/pdf/uscs-public-use-database-technical-documentation-us-2001-2018-508.pdf (accessed on 8 June 2022).
- List of SEER Registries. Available online: https://seer.cancer.gov/registries/list.html (accessed on 3 January 2023).
- Anderson, W.F.; Camargo, M.C.; Fraumeni, J.F., Jr.; Correa, P.; Rosenberg, P.S.; Rabkin, C.S. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 2010, 303, 1723–1728. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, H.J.; Fay, M.P.; Feuer, E.J.; Midthune, D.N. Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 2000, 19, 335–351. [Google Scholar] [CrossRef]
- Kim, H.J.; Fay, M.P.; Yu, B.; Barrett, M.J.; Feuer, E.J. Comparability of segmented line regression models. Biometrics 2004, 60, 1005–1014. [Google Scholar] [CrossRef]
- Feder, P.I. On Asymptotic Distribution Theory in Segmented Regression Problems—Identified Case. Ann. Statist. 1975, 3, 49–83. [Google Scholar] [CrossRef]
- Hofferkamp, J.; Havener, L.A. Standards for Cancer Registries: Data Standards and Data Dictionary, 12th ed.; North American Association of Central Cancer Registries: Springfield, IL, USA, 2007. [Google Scholar]
- Xu, J.; Lin, Y.; Yang, M.; Zhang, L. Statistics and pitfalls of trend analysis in cancer research: A review focused on statistical packages. J. Cancer 2020, 11, 2957–2961. [Google Scholar] [CrossRef] [PubMed]
- Merchant, S.J.; Kim, J.; Choi, A.H.; Sun, V.; Chao, J.; Nelson, R. A rising trend in the incidence of advanced gastric cancer in young Hispanic men. Gastric Cancer 2017, 20, 226–234. [Google Scholar] [CrossRef] [PubMed]
- Tseng, J.; Miller, J.P.; Johnson, J.; Waters, K.; Gangi, A.; Gong, J.; Burch, M. Disparities and survival in newly diagnosed gastric cancer in Hispanic patients in the United States: A propensity score matched analysis. J. Gastrointest. Oncol. 2021, 12, 1308–1325. [Google Scholar] [CrossRef] [PubMed]
- Ishaq, S.; Nunn, L. Helicobacter pylori and gastric cancer: A state of the art review. Gastroenterol. Hepatol. Bed Bench 2015, 8 (Suppl. S1), S6–S14. [Google Scholar]
- Brown, H.; Cantrell, S.; Tang, H.; Epplein, M.; Garman, K.S. Racial Differences in Helicobacter pylori Prevalence in the US: A Systematic Review. Gastro Hep Adv. 2022, 1, 857–868. [Google Scholar] [CrossRef] [PubMed]
- Thrift, A.P.; Wenker, T.N.; El-Serag, H.B. Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention. Nat. Rev. Clin. Oncol. 2023. [Google Scholar] [CrossRef]
- Smet, A.; Kupcinskas, J.; Link, A.; Hold, G.L.; Bornschein, J. The Role of Microbiota in Gastrointestinal Cancer and Cancer Treatment: Chance or Curse? Cell. Mol. Gastroenterol. Hepatol. 2022, 13, 857–874. [Google Scholar] [CrossRef]
- Yao, Q.; Qi, X.; Xie, S.-H. Sex difference in the incidence of cardia and non-cardia gastric cancer in the United States, 1992–2014. BMC Gastroenterol. 2020, 20, 418. [Google Scholar] [CrossRef] [PubMed]
- Yoo, J.E.; Shin, D.W.; Han, K.; Kim, D.; Jeong, S.M.; Koo, H.Y.; Yu, S.J.; Park, J.; Choi, K.S. Association of the Frequency and Quantity of Alcohol Consumption With Gastrointestinal Cancer. JAMA Netw. Open 2021, 4, e2120382. [Google Scholar] [CrossRef]
- Palli, D.; Galli, M.; Caporaso, N.E.; Cipriani, F.; Decarli, A.; Saieva, C.; Fraumeni, J.F., Jr.; Buiatti, E. Family history and risk of stomach cancer in Italy. Cancer Epidemiol. Biomark. Prev. 1994, 3, 15–18. [Google Scholar]
- Shin, C.M.; Kim, N.; Yang, H.J.; Cho, S.I.; Lee, H.S.; Kim, J.S.; Jung, H.C.; Song, I.S. Stomach cancer risk in gastric cancer relatives: Interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. J. Clin. Gastroenterol. 2010, 44, e34–e39. [Google Scholar] [CrossRef] [Green Version]
- Ratti, M.; Lampis, A.; Hahne, J.C.; Passalacqua, R.; Valeri, N. Microsatellite instability in gastric cancer: Molecular bases, clinical perspectives, and new treatment approaches. Cell. Mol. Life Sci. 2018, 75, 4151–4162. [Google Scholar] [CrossRef] [PubMed]
- Minalyan, A.; Benhammou, J.N.; Artashesyan, A.; Lewis, M.S.; Pisegna, J.R. Autoimmune atrophic gastritis: Current perspectives. Clin. Exp. Gastroenterol. 2017, 10, 19–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, M.; Camargo, M.C.; Katki, H.A.; Weinstein, S.J.; Mannisto, S.; Albanes, D.; Surcel, H.M.; Rabkin, C.S. Association of Antiparietal Cell and Anti-Intrinsic Factor Antibodies with Risk of Gastric Cancer. JAMA Oncol. 2022, 8, 268–274. [Google Scholar] [CrossRef] [PubMed]
- Torres-Bondia, F.; de Batlle, J.; Galvan, L.; Buti, M.; Barbe, F.; Pinol-Ripoll, G. Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015. BMC Public Health 2022, 22, 818. [Google Scholar] [CrossRef] [PubMed]
- Midthune, D.N.; Fay, M.P.; Clegg, L.X.; Feuer, E.J. Modeling Reporting Delays and Reporting Corrections in Cancer Registry Data. J. Am. Stat. Assoc. 2005, 100, 61–70. [Google Scholar] [CrossRef]
- Kehm, R.D.; Yang, W.; Tehranifar, P.; Terry, M.B. 40 Years of Change in Age- and Stage-Specific Cancer Incidence Rates in US Women and Men. JNCI Cancer Spectr. 2019, 3, pkz038. [Google Scholar] [CrossRef]
Figure 1.
(A) In SEER, among those aged ≥55 years, APC in men is decreasing at a greater rate than in women with non-parallel trends (AAPC −2.44% vs. −1.64%; p-value < 0.01). (B) In SEER, among those aged <55 years, incidence increased in women but remained stable in men (AAPC 2.01% vs. 0.29%; p-value < 0.01). (C,D) In SEER-Independent NPCR, both findings in those of age ≥55 and <55 were similar to the analyses of SEER database.
Figure 1.
(A) In SEER, among those aged ≥55 years, APC in men is decreasing at a greater rate than in women with non-parallel trends (AAPC −2.44% vs. −1.64%; p-value < 0.01). (B) In SEER, among those aged <55 years, incidence increased in women but remained stable in men (AAPC 2.01% vs. 0.29%; p-value < 0.01). (C,D) In SEER-Independent NPCR, both findings in those of age ≥55 and <55 were similar to the analyses of SEER database.
Figure 2.
(A–D) Sex-specific incidence trends among younger adults by race. All data are from SEER database, among those of age < 55 years. Lines of both men and women are same colors if trends are parallel, meaning same APC and AAPC values during the interval years. (A) In Non-Hispanic Whites, APC in women is increasing at a greater rate than in men with non-parallel trends (AAPC 2.28% vs. 0.58%; p-value < 0.04). (B–D) In Non-Hispnanic Blacks, Hispanics, and Asian/Pacific Islanders, incidence trends in women and men were identical but not parallel (p-values 0.06, 0.17, 0.32, respectively).
Figure 2.
(A–D) Sex-specific incidence trends among younger adults by race. All data are from SEER database, among those of age < 55 years. Lines of both men and women are same colors if trends are parallel, meaning same APC and AAPC values during the interval years. (A) In Non-Hispanic Whites, APC in women is increasing at a greater rate than in men with non-parallel trends (AAPC 2.28% vs. 0.58%; p-value < 0.04). (B–D) In Non-Hispnanic Blacks, Hispanics, and Asian/Pacific Islanders, incidence trends in women and men were identical but not parallel (p-values 0.06, 0.17, 0.32, respectively).
Figure 3.
(A–C) Sex-specific incidence trends among younger adults by histopathology based on Lauren’s criteria. All data are from SEER database, among those of age < 55 years. Lines of both men and women are same colors if trends are parallel, meaning same APC and AAPC values during the interval years. (A,B) Based on Lauren’s criteria, both intestinal and diffuse subtype groups showed parallel incidence trends between men and women (p-values 0.29 and 0.83, respectively). (C) Of the unspecified subtype, women had statistically significant increase in incidence compared to counterpart men in nonparallel trend (AAPC 3.62% vs. 0.43%; p-value < 0.01).
Figure 3.
(A–C) Sex-specific incidence trends among younger adults by histopathology based on Lauren’s criteria. All data are from SEER database, among those of age < 55 years. Lines of both men and women are same colors if trends are parallel, meaning same APC and AAPC values during the interval years. (A,B) Based on Lauren’s criteria, both intestinal and diffuse subtype groups showed parallel incidence trends between men and women (p-values 0.29 and 0.83, respectively). (C) Of the unspecified subtype, women had statistically significant increase in incidence compared to counterpart men in nonparallel trend (AAPC 3.62% vs. 0.43%; p-value < 0.01).
Figure 4.
(A–D) Sex-specific incidence trends among younger adults by staging at diagnosis. All data are from SEER database, among those of age < 55 years. Lines of both men and women are same colors if trends are parallel, meaning same APC and AAPC values during the interval years. (A) Among patients with localized stage of disease at diagnosis, women had higher increase in incidence than men (AAPC 5.17% vs. 2.04%; p-value < 0.03). (B–D) Among those with regional, distant, or unknown/unstaged staging at diagnosis, the trends between men and women were parallel (p-values 0.47, 0.94, 0.37, respectively).
Figure 4.
(A–D) Sex-specific incidence trends among younger adults by staging at diagnosis. All data are from SEER database, among those of age < 55 years. Lines of both men and women are same colors if trends are parallel, meaning same APC and AAPC values during the interval years. (A) Among patients with localized stage of disease at diagnosis, women had higher increase in incidence than men (AAPC 5.17% vs. 2.04%; p-value < 0.03). (B–D) Among those with regional, distant, or unknown/unstaged staging at diagnosis, the trends between men and women were parallel (p-values 0.47, 0.94, 0.37, respectively).
Table 1.
Overall Incidence Rates (per 100,000 population) of Primary Non-cardia Gastric Cancer in the U.S.
Table 1.
Overall Incidence Rates (per 100,000 population) of Primary Non-cardia Gastric Cancer in the U.S.
| SEER Database 2000–2018 (N = 79,068) | ||||
|---|---|---|---|---|
| Age | Overall | Women | Men | aIRR * |
| All Ages | 3.56 (3.54–3.59) | 2.91 (2.88–2.94) | 4.44 (4.39–4.48) | 0.66 |
| ≥55 | 13.59 (13.49–13.70) | 10.71 (10.59–10.84) | 17.54 (17.35–17.72) | 0.61 |
| <55 | 1.15 (1.13–1.16) | 1.09 (1.06–1.11) | 1.21 (1.18–1.24) | 0.90 |
| Age < 55 years (N = 13,791) | ||||
| Race/Ethnicity | Overall | Women | Men | aIRR * |
| Non-Hispanic White | 0.62 (0.60–0.64) | 0.60 (0.57–0.62) | 0.64 (0.61–0.67) | 0.94 |
| Non-Hispanic Black | 1.80 (1.73–1.87) | 1.52 (1.43–1.61) | 2.11 (2.00–2.23) | 0.72 |
| Hispanic | 1.97 (1.91–2.03) | 1.90 (1.82–1.99) | 2.04 (1.95–2.13) | 0.93 |
| Asian/Pacific Islander | 2.02 (1.94–2.11) | 1.91 (1.81–2.03) | 2.15 (2.02–2.27) | 0.89 |
| Other | 1.59 (1.33–1.89) | 1.40 (1.06–1.81) | 1.80 (1.41–2.26) | 0.78 |
| Histopathology | ||||
| Intestinal Subtype a | 0.11 (0.11–0.12) | 0.08 (0.07–0.09) | 0.15 (0.14–0.16) | 0.53 |
| Diffuse Subtype b | 0.44 (0.43–0.45) | 0.46 (0.44–0.48) | 0.43 (0.41–0.44) | 1.07 |
| Other/Unspecified c | 0.58 (0.57–0.59) | 0.54 (0.52–0.56) | 0.62 (0.60–0.64) | 0.87 |
| Stage at Diagnosis (2004–2018) | ||||
| Localized | 0.34 (0.33–0.35) | 0.37 (0.35–0.39) | 0.31 (0.30–0.33) | 1.19 |
| Regional | 0.32 (0.31–0.33) | 0.28 (0.27–0.30) | 0.35 (0.34–0.37) | 0.80 |
| Distant | 0.40 (0.39–0.41) | 0.37 (0.35–0.39) | 0.43 (0.42–0.45) | 0.86 |
| Unstaged/Unknown | 0.06 (0.06–0.07) | 0.07 (0.06–0.07) | 0.06 (0.05–0.07) | 1.17 |
| SEER-Independent NPCR Database 2001–2018 (N = 90,760) | ||||
| Age Groups | Overall | Women | Men | aIRR * |
| All Ages | 2.47 (2.46–2.49) | 2.03 (2.01–2.05) | 3.06 (3.03–3.09) | 0.66 |
| ≥55 | 9.45 (9.27–9.40) | 7.37 (7.29–7.45) | 11.97 (11.85–12.08) | 0.62 |
| <55 | 0.83 (0.82–0.85) | 0.79 (0.77–0.81) | 0.88 (0.86–0.90) | 0.90 |
Age and sex-specific NCGC incidence rates and women to men incidence rate ratios (aIRR) from SEER database, and SEER-Independent NPCR Database. Data are presented as aIR (95% CI). aIRR *: adjusted incidence rate ratio (women: men). a: ICD-O-3 codes: 8012, 8021, 8022, 8031, 8032, 8046, 8050, 8082, 8143, 8144, 8201, 8210, 8211, 8220, 8221, 8255, 8260, 8261, 8262, 8263, 8310, 8323, 8480, 8481, 8510, 8512, 8570, and 8576. b: ICD-O-3 codes: 8020, 8041, 8044, 8141, 8142, 8145, 8490, and 8806. c: ICD-O-3 codes: 8000, 8010, 8140, 8210, 8240, 8246, 8249, 8890, and 8936.
Table 2.
(A) SEER Database (2000–2018): Age and Sex-Specific Trends of Non-cardia Gastric Cancer in the United States. (B) SEER-Excluded NPCR Database (2001–2018): Age and Sex-Specific Trends of Non-cardia Gastric Cancer in the United States.
Table 2.
(A) SEER Database (2000–2018): Age and Sex-Specific Trends of Non-cardia Gastric Cancer in the United States. (B) SEER-Excluded NPCR Database (2001–2018): Age and Sex-Specific Trends of Non-cardia Gastric Cancer in the United States.
| (A) | |||||||
| Trends | Pairwise Comparison | ||||||
| Sex | Cases n (% of Age Group) | Years | APC (95%CI) | AAPC a (95%CI) | AAPC p-Value b | Test of Coincidence p-Value c | Test of Parallelism p-Value d |
| All Ages (N = 79,068) | |||||||
| Men | 42,965 (54.3%) | 2000–2018 | −1.73% (−1.94–−1.51) | −1.73% (−1.94–−1.51) | <0.001 | <0.001 | <0.001 |
| Women | 36,103 (45.7%) | 2000–2018 | −0.60% (−0.80–−0.40) | −0.60% (−0.80–−0.40) | <0.001 | ||
| Age ≥ 55 (N = 65,258) | |||||||
| Men | 35,747 (54.8%) | 2000–2018 | −2.16% (−2.38–−1.95) | −2.16% (−2.38–−1.95) | <0.001 | <0.001 | <0.001 |
| Women | 29,511 (45.2%) | 2000–2018 | −1.37% (−1.61–−1.12) | −1.37% (−1.61–−1.12) | <0.001 | ||
| Age < 55 (N = 13,791) | |||||||
| Men | 7212 (52.3%) | 2000–2018 | 0.68% (0.06–1.30) | 0.68% (0.06–1.30) | 0.033 | <0.001 | 0.015 |
| Women | 6579 (47.7%) | 2000–2018 | 2.28% (1.82–2.74) | 2.28% (1.82–2.74) | <0.001 | ||
| (B) | |||||||
| Trends | Pairwise Comparison | ||||||
| Sex | Cases n (% of Age Group) | Years | APC (95%CI) | AAPC a (95%CI) | AAPC p-Value b | Test of Coincidence p-Value c | Test of Parallelism p-Value d |
| All Ages (N = 90,760) | |||||||
| Men | 49,740 (54.8%) | 2001–2006 | −2.92% (−4.42–−1.39) | −1.55% (−2.37–−0.73) | <0.001 | <0.001 | <0.001 |
| 2006–2016 | −0.23% (−0.83–0.37) | ||||||
| 2016–2018 | −4.61% (−10.50–1.66) | ||||||
| Women | 41,020 (45.2%) | 2001–2005 | −2.36% (−5.55–0.94) | −0.19% (−0.98–−0.61) | 0.65 | ||
| 2005–2018 | 0.49% (−0.04–1.02) | ||||||
| Age ≥ 55 (N = 75,241) | |||||||
| Men | 41,585 (55.3%) | 2001–2006 | −3.39% (−5.11–1.63) | −2.06% (−3.01–−1.11) | <0.001 | <0.001 | 0.009 |
| 2006–2016 | −0.72% (−1.41–−0.02) | ||||||
| 2016–2018 | −5.39% (−12.12–1.87) | ||||||
| Women | 33,656 (44.7%) | 2001–2018 | −0.82% (−1.22–−0.43) | −0.82% (−1.22–−0.43) | <0.001 | ||
| Age < 55 (N = 15,486) | |||||||
| Men | 8144 (52.6%) | 2001–2018 | 1.51% (1.04–1.98) | 1.51% (1.04–1.98) | <0.001 | <0.001 | <0.001 |
| Women | 7342 (47.4%) | 2001–2018 | 3.22% (2.69–3.77) | 3.22% (2.69–3.77) | <0.001 | ||
a: AAPC is calculated as average of APCs over the designated time period. b: For all ages, AAPCs with p-values < 0.05 were considered significant. c: Tests whether sex-specific trends were identical. p-value < 0.05 signifies trends were not identical. d: Tests whether sex-specific trends were equal and parallel. p-value < 0.05 signifies the trends were not equal.
Table 3.
Age and Sex-Specific Trends of Non-cardia Gastric Cancer Among Race and Histology Subgroups in Those of Ages < 55 Years, SEER Database 2000–2018 (N = 13,791).
Table 3.
Age and Sex-Specific Trends of Non-cardia Gastric Cancer Among Race and Histology Subgroups in Those of Ages < 55 Years, SEER Database 2000–2018 (N = 13,791).
| Trends | Pairwise Comparison | |||||||
|---|---|---|---|---|---|---|---|---|
| Subgroup | Sex | Cases n (% of Age Group) | Years | APC (95%CI) | AAPC a (95%CI) | AAPC p-Value b | Test of Coincidence p-Value c | Test of Parallelism p-Value d |
| Race | ||||||||
| Non-Hispanic White | Male | 2375 (17.2%) | 2000–2018 | 0.58% (−0.42–1.59) | 0.58% (−0.42–1.59) | 0.082 | <0.001 | 0.042 |
| Female | 2169 (15.7%) | 2000–2018 | 2.28% (1.38–3.19) | 2.28% (1.38–3.19) | 0.005 | |||
| Non-Hispanic Black | Male | 1395 (10.1%) | 2000–2018 | −0.59% (−1.49–0.31) | −0.59% (−1.49–0.31) | 0.19 | <0.001 | 0.062 |
| Female | 1129 (8.2%) | 2000–2018 | ||||||
| Hispanic | Male | 2172 (15.7%) | 2000–2018 | 0.84% (0.14–1.53) | 0.84% (0.14–1.53) | 0.020 | <0.001 | 0.17 |
| Female | 2027 (14.7%) | 2000–2018 | ||||||
| Asian/Pacific Islander | Male | 1170 (8.5%) | 2000–2002 | 14.73% (−10.72–47.42) | 0.10% (−2.63–2.91) | 0.94 | <0.001 | 0.32 |
| 2002–2018 | −1.59% (−2.39–−0.79) | |||||||
| Female | 1173 (8.5%) | 2000–2002 | 14.73% (−10.72–47.42) | <0.001 | 0.32 | |||
| 2002–2018 | −1.59% (−2.39–−0.79) | |||||||
| Other/Unspecified | Male | 72 (0.01%) | 2000–2018 | Could not analyze | <0.001 | - | ||
| Female | 57 (0.004%) | 2000–2018 | Could not analyze | |||||
| Histology | ||||||||
| Intestinal e | Male | 886 (6.4%) | 2000–2018 | 2.09% (0.95–3.24) | 2.09% (0.95–3.24) | 0.001 | <0.001 | 0.29 |
| Female | 478 (3.5%) | 2000–2018 | ||||||
| Diffuse f | Male | 2514 (18.2%) | 2000–2018 | 0.84% (0.20–1.47) | 0.84% (0.20–1.47) | 0.011 | 0.11 | 0.83 |
| Female | 2766 (20.1%) | 2000–2018 | ||||||
| Other/Unspecified g | Male | 3736 (27.1%) | 2000–2018 | 0.43% (−0.4–1.21) | 0.43% (−0.4–1.21) | 0.26 | <0.001 | <0.001 |
| Female | 3274 (23.7%) | 2000–2018 | 3.62% (2.99–4.26) | 3.62% (2.99–4.26) | <0.001 | |||
| Stage at Diagnosis | ||||||||
| Localized | Male | 1503 (10.9%) | 2004–2018 | 2.04% (0.33–3.78) | 2.04% (0.33–3.78) | 0.023 | 0.004 | 0.025 |
| Female | 1780 (12.9%) | 2004–2018 | 5.17% (4.04–6.31) | 5.17% (4.04–6.31) | <0.001 | |||
| Regional | Male | 1692 (12.3%) | 2004–2018 | −1.08% (−1.94–−0.20) | −1.08% (−1.94–−0.20) | 0.018 | <0.001 | 0.47 |
| Female | 1352 (9.8%) | 2004–2018 | ||||||
| Distant | Male | 2050 (14.9%) | 2004–2018 | 0.81% (0.04–1.58) | 0.81% (0.04–1.58) | 0.039 | 0.001 | 0.94 |
| Female | 1756 (12.7%) | 2004–2018 | ||||||
| Unknown/Unstaged | Male | 288 (2.1%) | 2004–2018 | 2.61% (0.20–5.08) | 2.61% (0.20–5.08) | 0.035 | 0.58 | 0.36 |
| Female | 317 (2.3%) | 2004–2018 | ||||||
a: AAPC is calculated as average of APCs over the designated time period. b: For all ages, AAPCs with p-values < 0.05 were considered significant. c: Tests whether sex-specific trends were identical. p-value < 0.05 signifies trends were not identical. d: Tests whether sex-specific trends were equal and parallel. p-value < 0.05 signifies the trends were not equal. e: ICD-O-3 codes: 8012, 8021, 8022, 8031, 8032, 8046, 8050, 8082, 8143, 8144, 8201, 8210, 8211, 8220, 8221, 8255, 8260, 8261, 8262, 8263, 8310, 8323, 8480, 8481, 8510, 8512, 8570, and 8576. f: ICD-O-3 codes: 8020, 8041, 8044, 8141, 8142, 8145, 8490, and 8806. g: ICD-O-3 codes: 8000, 8010, 8140, 8210, 8240, 8246, 8249, 8890, and 8936.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Oh, J.; Abboud, Y.; Burch, M.; Gong, J.; Waters, K.; Ghaith, J.; Jiang, Y.; Park, K.; Liu, Q.; Watson, R.; et al. Rising Incidence of Non-Cardia Gastric Cancer among Young Women in the United States, 2000–2018: A Time-Trend Analysis Using the USCS Database. Cancers 2023, 15, 2283. https://doi.org/10.3390/cancers15082283
AMA Style
Oh J, Abboud Y, Burch M, Gong J, Waters K, Ghaith J, Jiang Y, Park K, Liu Q, Watson R, et al. Rising Incidence of Non-Cardia Gastric Cancer among Young Women in the United States, 2000–2018: A Time-Trend Analysis Using the USCS Database. Cancers. 2023; 15(8):2283. https://doi.org/10.3390/cancers15082283
Chicago/Turabian StyleOh, Janice, Yazan Abboud, Miguel Burch, Jun Gong, Kevin Waters, Jenan Ghaith, Yi Jiang, Kenneth Park, Quin Liu, Rabindra Watson, and et al. 2023. "Rising Incidence of Non-Cardia Gastric Cancer among Young Women in the United States, 2000–2018: A Time-Trend Analysis Using the USCS Database" Cancers 15, no. 8: 2283. https://doi.org/10.3390/cancers15082283
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
